# Rampart IC

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rampart-ic

- Industry: Healthcare IT
- Headquarters: Birmingham, US
- Website: www.rampartic.com/
- Total disclosed funding: $22M
- Latest round: Series B (Apr 24, 2025)
- Investors on record: 1

## About

Rampart ic, LLC focuses on innovative radiation protection solutions, enhancing safety for healthcare professionals during interventional procedures through advanced shielding products designed for functionality and ease of use.Rampart ic, LLC, founded in 2014 in Birmingham, US, specializes in advanced radiation protection solutions. The company has not undergone any significant pivot in its business strategy. It was established by a group of individuals committed to improving safety for medical professionals. The founder has a background in health technology and has previously founded other companies in the medical device sector. Rampart ic operates globally, serving clients primarily in North America, Europe, and Asia. As of April 2025, the company raised USD 21.6 mn in Series B funding led by Vensana Capital, bringing the total amount raised to USD 21.6 mn.Rampart ic specializes in advanced radiation protection solutions designed to enhance safety for healthcare professionals during interventional procedures. The core product offerings include the Rampart Guardian, Defender, Bunker, Sentry, and Shadow, each engineered to block scatter radiation without the weight and limitations of traditional lead aprons. These innovative products are characterized by their modular design, allowing for easy integration into various interventional suites, thus improving workflow without compromising patient safety. Rampart's solutions are utilized primarily in cath labs, electrophysiology labs, and interventional suites by a diverse client base that includes leading hospitals and healthcare facilities across North America, Europe, and Asia. By addressing the inadequacies of conventional radiation protection methods, Rampart ic aims to provide comprehensive safety to entire procedural teams rather than solely focusing on operators.Rampart ic generates revenue through direct sales of its radiation shielding products to healthcare institutions and medical professionals. The business transactions typically involve B2B relationships, where hospitals and clinics place orders for the various shielding systems based on their operational needs. The products are marketed as premium solutions designed to eliminate the physical burdens of lead while ensuring superior protection; therefore, the pricing structure reflects the advanced technology and benefits they provide. The Rampart Guardian and Defender, recognized as flagship products, are positioned to capture a significant share of the market by offering measurable reductions in radiation exposure, backed by extensive clinical research. The company has established a model that emphasizes long-term partnerships, focusing on the implementation of its products in healthcare settings to enhance procedural safety and efficiency.In April 2025, Rampart ic, LLC raised USD 21.6 mn in Series B funding led by Vensana Capital. The company will utilize this funding to accelerate business expansion and increase accessibility by being available to more hospitals. Rampart ic plans to launch new products that enhance radiation protection solutions, with targeted releases planned for late 2025. Furthermore, expansion efforts are aimed at entering additional healthcare markets across Europe and Asia by the end of 2025.

## Funding rounds

- Series B, Apr 24, 2025, $22M — Vensana Capital

## Investors

- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series B